ABSTRACT
Background To externally validate the 4-variable Kidney Failure Risk Equation (KFRE) in the Peruvian population for predicting kidney failure at 2 and 5 years.
Methods We included patients from 17 primary care centers from the Health’s Social Security of Peru. Patients older than 18 years, diagnosed with chronic kidney disease (CKD) stage 3a-3b-4 and 3b-4, between January 2013 and December 2017. Patients were followed until they developed kidney failure, died, were lost, or ended the study (December 31, 2019), whichever came first. Performance of the KFRE model was assessed based on discrimination and calibration measures considering the competing risk of death.
Results We included 7519 patients in stages 3a-4 and 2,798 patients in stages 3b-4. KFRE discrimination at 2 and 5 years was high, with Time-Dependent Area Under the Curve (AUC-td) and C-index > 0.8 for all populations. Regarding calibration in-the-large, the Observed-to-Expected (O/E) ratio and the calibration intercept indicated that KFRE underestimates the overall risk at two years and overestimates it at 5-years in all populations.
Conclusions The 4-variable KFRE models have good discrimination but poor calibration in the Peruvian population. The model underestimates the risk of kidney failure in the short term and overestimates it in the long term.
SIGNIFICANCE STATEMENT The Kidney Failure Risk Equation (KFRE) is a widely used prediction model for kidney failure risk assessment in patients with chronic kidney disease (CKD). However, its performance in Latin American populations remains unclear, particularly in primary care settings. This study externally validated the KFRE in Peruvian CKD patients, demonstrating high discrimination but revealing miscalibration that could lead to adverse patient outcomes resulting from over- or under-estimation of risk. These results underscore the need for model updating and further research to optimize the KFRE’s use in clinical practice in Latin America, provide valuable insights for applying the KFRE in Latin American settings, and highlight the importance of continuous evaluation and refinement of prediction models in diverse populations.
Competing Interest Statement
JBZ and RCG are full-time employees of EsSalud, and PSB has received consultancy fees from EsSalud. However, the authors affirm that their respective affiliations with EsSalud have not influenced any aspect of the study, including study design, data collection, analysis, interpretation, or manuscript preparation. The authors declare that there are no other competing interests or potential conflicts of interest related to the content of this manuscript.
Funding Statement
This study was entirely self-funded by the authors and did not receive any external financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee of the Edgardo Rebagliati National Hospital approved this study (575-GRPR-ESSALUD-2021). Because all the data from clinical registries were anonymized before being processed for the research, the ethics committee accepted the waiver of informed consent from the patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title has been updated to comply with the maximum word limit of the new journal to which the manuscript has been submitted. The structured abstract has been adapted to match the submission format of the new journal; the introduction, results, and discussion sections have been condensed to align with the word limit of the new journal. A description regarding ethnicity has been added to the methods section.
Data Availability
The analysis code essential for the replication of study findings can be accessed at this link: https://github.com/psotob91/kfre-ckd-reba-peru. As per the privacy policies of EsSalud, the minimal data set is not open to public access. However, we are amenable to providing the anonymised data upon receipt of a reasonable request directed to the corresponding author (psoto{at}continental.edu.pe).
